Swiss pharmaceutical giant Novartis has signed an initial deal to produce the mRNA molecules for the Covid-19 vaccine developed by German biotech firm CureVac.
This content was published on
2 minutes
Keystone-SDA/jdp
Português
pt
Multinacional Novartis vai ajudar a produzir vacina CureVac Covid-19
On Thursday, Novartis said its plant in Kundl, Austria, would start production of the CureVac vaccine (CVnCoV) this summer. It hopes to deliver enough drug substance to produce 50 million doses by the end of the year and plans to accelerate production to reach 200 million doses in 2022. CureVac is also working with German pharmaceutical company Bayer to manufacture its vaccine.
“We are currently expanding our site with additional capacities for the production of mRNA in order to best serve the increasing demand,” said Steffen Lang, Global Head of Novartis Technical Operations, in a press release.
At the end of January, Novartis announced it would also provide manufacturing capacity for Pfizer/BioNTech’s Covid-19 vaccine. Under the deal, Novartis is involved in the fill-and-finish process – taking the bulk mRNA active ingredient from BioNTech and putting it into vials at its facility in Stein, Switzerland.
Novartis says it is considering other agreements to support the global supply of Covid-19 vaccines and therapeutics.
Switzerland has reserved over 30 million vaccine doses from different manufacturers – Pfizer/BioNTech, Moderna, AstraZeneca, Curevac and Novavax – for its population of 8.6 million people. So far, there are two vaccines approved and available in the country, those from Pfizer/BioNTech and Moderna.
The Swiss government secured 5 million doses of the CureVac vaccine in February. It is based on similar mRNA technology as the Pfizer/BioNtech and Moderna vaccines. Swiss firm Lonza is producing the main active vaccine ingredients for the Moderna vaccine for non-US markets at its site in Visp in southern Switzerland.
Swiss money laundering office registers record number of reports
This content was published on
The Money Laundering Reporting Office Switzerland (MROS) registered a record number of reports of suspicious activity last year.
Two teens accused of planning terror attack released from custody
This content was published on
The Schaffhausen judiciary has released the two teenagers from custody who allegedly planned bomb attacks in Switzerland.
OECD: Sluggish economic activity slowing growth in Switzerland
This content was published on
Sluggish economic activity at the start of the year is weighing on growth in Switzerland, with GDP expected to fall to 1.1% in 2024.
Report finds mistakes which led to Swiss government data breach
This content was published on
Mistakes were made by both the government and internet company Xplain in the case of a criminal cyber-attack on the Bern-based IT business.
Swiss government wants better gender balance in federal administration
This content was published on
New Swiss government personnel management targets say there must be even more female managers in the federal administration.
Swiss national science foundation funded over 5,000 projects in 2023
This content was published on
In 2023, the Swiss National Science Foundation (SNSF) provided a total of CHF961 million worth of funding towards research projects.
Calls intensify for Big Pharma to break monopolies on Covid-19 vaccines
This content was published on
Pressure is mounting to suspend intellectual property rules to help vaccines reach more people. Can the WTO find a solution?
Novartis agrees to help Pfizer-BioNTech produce Covid-19 vaccine
This content was published on
Swiss pharma giant Novartis says it has signed an initial agreement to provide manufacturing capacity for Pfizer and BioNTech's Covid-19 vaccine.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.